Shortage began in August and has increased the onset of cough/cold season due to consumers’ “stockpiling/panic buying” in response to high levels of activity in COVID-19, RSV, seasonal flu and other viruses, according to Canadian Pharmacists Association. Health Canada has approved imports of Haleon and J&J children’s pain relievers.

Foreign cosmetic product manufacturers may avoid the Chinese market if burdensome registration requirements aren’t modified and fairness issues addressed, the trade association says in comments to the Office of the US Trade Representative.

Citing national uncertainty regarding reproductive health care – “ a time when reproductive rights have been curtailed across the country – state AGs urge FDA to approve OTC birth control proposal from HRA Pharma.

SymptoPro Fertility Education focuses comments to FDA on potential side effects from Opill, suggesting its use could be linked to increased breast cancer risk, depression and ectopic pregnancy. Guttmacher Institute supports approval, saying “adolescents have most to gain.”

As pharma marketing and Rx-to-OTC switch experts told HBW Insight, health care industry stakeholders submitting comments to the FDA connect Opill NDA to FDA’s consideration of an ACNU pathway.

Industry self-regulation group’s appeals board agrees with investigative division’s finding Sanofi didn’t support Zantac 360 “#1 doctor recommended” ad claims. Board declines to consider whether “#1 doctor recommended H2 active ingredient” with “based on generic acid reducer recommendations” disclaimer is supported.